The two companies aim to produce four billion doses of the vaccine next year, mostly for low- and middle-income countries.
And full approval of the vaccine, which the US Food and Drug Administration has approved for emergency use, can help reduce the reluctance to use it in the United States and other rich countries.
Pfizer also cited the new expectations of increased production as evidence of its ability and determination to serve the poorest countries that have received very little of their vaccine so far.
In a letter to pfizer workers, which was published, CEO Albert Burla said that the company already has deals or is in talks with countries to supply 2.7 billion doses of the vaccine this year, 40% of which are expected to go to low- and middle-income countries.
Pfizer and BioNTech said the FDA will set a date for a decision once the application is formally accepted for consideration.